MPN中B4GALT1表达升高与血小板表面半乳糖基化及血浆TPO水平相关
本研究探讨骨髓增殖性肿瘤(MPN)中异常巨核细胞生成与血小板糖基化的关系。发现MPN患者血浆TPO水平升高且与突变克隆负荷高相关,血小板LacNAc表达显著增加并与等位基因负荷相关;体外培养的MPN巨核细胞B4GALT1表达增加,LacNAc表达升高可被JAK1/2抑制剂逆转。提示B4GALT1异常表达导致血小板半乳糖基化异常,进而促进肝脏TPO合成。
要点
- MPN患者血浆TPO水平升高且与突变克隆负荷高相关
- MPN血小板LacNAc表达显著增加并与等位基因负荷相关
- JAK1/2抑制剂可逆转MPN巨核细胞LacNAc表达升高
核心结论
- MPN中B4GALT1表达升高导致巨核细胞LacNAc表达增加,产生半乳糖基化异常的血小板,进而促进肝脏TPO合成。
- β4GalT1是MPN异常巨核细胞生成的潜在可干预靶点。
研究设计与样本
- 研究纳入MPN患者,检测血浆TPO水平、血小板LacNAc表达及体外培养巨核细胞B4GALT1表达。
主要发现
- MPN患者血浆TPO水平升高,且与突变克隆高等位基因负荷相关。
- MPN患者血小板LacNAc表达显著增加,与高等位基因负荷相关, regardless of underlying identified mutation。
- 体外培养的MPN患者巨核细胞B4GALT1表达增加,LacNAc表达高于健康对照,JAK1/2抑制剂可逆转。
临床怎么用
- 检测MPN患者血小板LacNAc表达和血浆TPO水平可能有助于评估异常巨核细胞生成。
- β4GalT1可作为MPN治疗的潜在靶点,JAK1/2抑制剂可降低巨核细胞LacNAc表达。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aberrant megakaryopoiesis is a hallmark of the myeloproliferative neoplasms (MPNs), a group of clonal hematological malignancies originating from hematopoietic stem cells, leading to an increase in mature blood cells in the peripheral blood. Sialylated derivatives of the glycan structure β4-N-acetyllactosamine (Galβ1,4GlcNAc or type-2 LacNAc, hereafter referred to as LacNAc) regulate platelet life span, hepatic thrombopoietin (TPO) production, and thrombopoiesis. We found increased TPO plasma levels in MPNs with high allele burden of the mutated clones. Remarkably, platelets isolated from MPNs had a significant increase in LacNAc expression that correlated with the high allele burden regardless of the underlying identified mutation. Megakaryocytes derived in vitro from these patients showed an increased expression of the B4GALT1 gene encoding β-1,4-galactosyltransferase 1 (β4GalT1). Consistently, megakaryocytes from MPN showed increased LacNAc expression relative to healthy controls, which was counteracted by the treatment with a Janus kinase 1/2 inhibitor. Altered expression of B4GALT1 in mutant megakaryocytes can lead to the production of platelets with aberrant galactosylation, which in turn promote hepatic TPO synthesis regardless of platelet mass. Our findings provide a new paradigm for understanding aberrant megakaryopoiesis in MPNs and identify β4GalT1 as a potential actionable target for therapy.
引用
- Di Buduo CA, Giannini S, Abbonante V, et al. Increased B4GALT1 expression is associated with platelet surface galactosylation and thrombopoietin plasma levels in MPNs. Blood. 2021. PMID: 33238000. doi:10.1182/blood.2020007265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。